Immortal Dragons Named Tier 4 Sponsor for ARDD 2025

The University of Copenhagen proudly announces Immortal Dragons as a Tier 4 sponsor for the upcoming 12th Aging Research and Drug Discovery (ARDD) Meeting, scheduled from August 25 to August 29, 2025. This prestigious conference, recognized as the world’s largest gathering dedicated to aging research within the biopharmaceutical industry, will be held on-site at the University’s Ceremonial Hall and simultaneously broadcasted online. The event serves as a vital platform convening leading scientists, innovators, investors, and healthcare professionals from across the globe to explore groundbreaking advancements in aging biology and therapeutic interventions.

Immortal Dragons, a forward-thinking longevity investment fund based in Singapore, is committed to accelerating radical life extension technologies. Unlike traditional investors who prioritize financial returns, Immortal Dragons focuses primarily on societal impact, underwriting cutting-edge startups engaged in transformative approaches such as whole-body replacement therapies, next-generation 3D bioprinting, advanced gene therapies, and innovative regulatory frameworks including special economic zones tailored for longevity biotech. Their investment philosophy challenges conventional aging paradigms by emphasizing the replacement of biological systems rather than mere repair, proposing a disruptive shift in combating aging.

This ethos is encapsulated by Founder Boyang Wang, who views aging as an engineering challenge solvable through technology and innovation. “Accepting aging and death as inevitable is a defeatist position. We believe that with the proper scientific breakthroughs and sustained advocacy, we can eradicate age-related diseases and significantly extend healthy human lifespan,” Wang asserts. Immortal Dragons thus operates not only as an investor but as an active participant in the longevity ecosystem through welfare grants, sponsorships, dissemination of knowledge via book translation and publishing, and hosting influential Chinese-language podcasts dedicated to longevity science.

ARDD 2025 promises a convergence of luminary figures, including Nobel laureates Morten Meldal and Michael Levitt, whose seminal contributions have revolutionized drug design and molecular modeling. Their pioneering work in molecular engineering and computational chemistry has laid the foundation for modern pharmacology and opened new avenues for creating targeted biomolecules with therapeutic potential. Their participation underscores the conference’s stature as an epicenter for multidisciplinary dialogue bridging fundamental research and clinical application in aging and drug discovery.

The conference embodies a unique fusion of academic excellence and industrial innovation, drawing leaders from leading pharmaceutical companies such as Novartis, Biogen, Eli Lilly, Regeneron, and Lundbeck. These industry giants actively engage with emerging research at ARDD, sharing insights into aging-related drug development pipelines and fostering collaborations aimed at translating molecular discoveries into viable medical interventions. The resulting synergies are instrumental in shaping the future trajectory of healthspan extension and age-associated disease amelioration.

A focal point at ARDD 2025 will be the special emphasis on Longevity Medicine, a novel discipline integrating clinical strategies and evidence-based approaches to healthy aging. This facet of the conference facilitates the exchange of clinical protocols, emerging therapies, and the application of artificial intelligence in medicine, targeting practitioners and researchers dedicated to preventive and regenerative healthcare. The inclusion of Longevity Medicine Day highlights an increasing recognition that extending lifespan necessitates a holistic approach encompassing molecular biology, pharmacology, and patient-centered clinical practice.

Moreover, ARDD serves as a melting pot for dialogues on technological innovation in longevity. Emerging tools such as AI-driven drug discovery platforms exemplify how computational methodologies are accelerating identification and optimization of molecules capable of modulating aging pathways. The integration of AI with traditional biopharmaceutical research is paving the way for unprecedented efficiency in understanding complex biological systems, unlocking therapeutic targets that were previously intractable.

The conference’s organizers stress the importance of grounding longevity science in rigorous, reproducible research. Professor Evelyne Bischof, organizer of the Longevity Medicine Days, emphasizes that the presence of Nobel laureates in the scientific roster highlights a commitment towards validated scientific excellence. “Our goal is to promote longevity interventions supported by robust evidence, ensuring that advancements in this burgeoning field meet the highest standards of scientific integrity,” she states.

ARDD’s role extends beyond fostering dialogue; it directly contributes to building an international collaborative network among academia, industry, and investors. This ecosystem is critical for overcoming the multifaceted challenges posed by aging—a complex biological phenomenon characterized by molecular damage accumulation, systemic decline, and increased vulnerability to diseases. Through partnerships catalyzed at ARDD, novel therapeutics designed to target fundamental aging mechanisms, such as senescence, proteostasis dysregulation, and mitochondrial dysfunction, are steadily moving from bench to bedside.

Recent years have witnessed accelerating momentum in the aging research arena, with substantial investments channeled towards pharmacological agents like senolytics, NAD+ precursors, and epigenetic modulators. ARDD serves as the principal stage for unveiling such advancements and engaging stakeholders in interactive sessions aimed at refining translational strategies. The conference also addresses regulatory, ethical, and societal considerations inherent in extending human healthspan, ensuring that scientific breakthroughs translate responsibly into clinical applications.

Importantly, the collaboration with Immortal Dragons adds a visionary partner focused on enabling ambitious, so-called “moonshot” projects which challenge established scientific dogmas. Their portfolio includes ventures exploring radical rejuvenation techniques and systemic replacement approaches aimed at restoring youthful biological functions. By nurturing such ventures, Immortal Dragons catalyzes an ecosystem that not only innovates incrementally but also dares to redefine the boundaries of human longevity.

In sum, ARDD 2025 presents a rare opportunity to witness and contribute to an accelerating confluence of science, technology, and medicine aimed at confronting one of humanity’s most profound challenges. Supported by a diverse constellation of thought leaders, investors, and industry titans, the event offers unparalleled insight into the future of aging research and drug discovery. As the world grapples with demographic shifts towards older populations, ARDD’s mission resonates with urgency and hope—a testament to the transformative potential of collaborative innovation in extending healthy lifespan.

For media inquiries and further information, please contact the organizing team at ardd@pharma.ai or reach out directly to Dr. Morten Scheibye-Knudsen of the University of Copenhagen at mscheibye@sund.ku.dk.

News Publication Date: Information not provided

Web References:

• University of Copenhagen: https://www.ku.dk/english/
• Aging Research & Drug Discovery Meeting: https://agingpharma.org/
• Immortal Dragons: Not provided directly, inferred as longevity investment fund headquartered in Singapore